Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic StimuliLIAN ZHANG; KAVANAGH, Brian D; THORBURN, Andrew M et al.Clinical cancer research (Print). 2010, Vol 16, Num 17, pp 4478-4489, issn 1078-0432, 12 p.Article

A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteersCAMIDGE, D. Ross; PEMBERTON, Mike; GROWCOTT, Jim et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 4, pp 479-488, issn 0344-5704, 10 p.Article

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesotheliomaCAMIDGE, D. Ross; BLAIS, Normand; CHOW, Laura Q et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 2, pp 307-319, issn 0344-5704, 13 p.Article

Ceritinib in ALK-Rearranged Non―Small-Cell Lung CancerSHAW, Alice T; KIM, Dong-Wan; RIELY, Gregory J et al.The New England journal of medicine. 2014, Vol 370, Num 13, pp 1189-1197, issn 0028-4793, 9 p.Article

Oncogene Status Predicts Patterns of Metastatic Spread in Treatment-Naive Nonsmall Cell Lung CancerDOEBELE, Robert C; XIAN LU; VARELLA-GARCIA, Marileila et al.Cancer. 2012, Vol 118, Num 18, pp 4502-4511, issn 0008-543X, 10 p.Article

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced MalignanciesCAMIDGE, D. Ross; HERBST, Roy S; BRAY, Gordon et al.Clinical cancer research (Print). 2010, Vol 16, Num 4, pp 1256-1263, issn 1078-0432, 8 p.Article

Drug-Induced Reduction in Estimated Glomerular Filtration Rate in Patients With ALK-Positive Non-Small Cell Lung Cancer Treated With the ALK Inhibitor CrizotinibBROSNAN, Evelyn M; WEICKHARDT, Andrew J; XIAN LU et al.Cancer. 2014, Vol 120, Num 5, pp 664-674, issn 0008-543X, 11 p.Article

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer HistologiesWYNES, Murry W; HINZ, Trista K; DZIADZIUSZKO, Rafal et al.Clinical cancer research (Print). 2014, Vol 20, Num 12, pp 3299-3309, issn 1078-0432, 11 p.Article

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung CancerSHAW, Alice T; KIM, Dong-Wan; WU, Yi-Long et al.The New England journal of medicine. 2013, Vol 368, Num 25, pp 2385-2394, issn 0028-4793, 10 p.Article

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation studyBLAIS, Normand; CAMIDGE, D. Ross; CHOW, Laura Q et al.Investigational new drugs. 2013, Vol 31, Num 6, pp 1487-1498, issn 0167-6997, 12 p.Article

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G₁ Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2SPRATLIN, Jennifer L; COHEN, Roger B; MEROPOL, Neal J et al.Journal of clinical oncology. 2010, Vol 28, Num 5, pp 780-787, issn 0732-183X, 8 p.Article

The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processesCAMIDGE, D. Ross; OLIVER, James J; SKINNE, Carolyn et al.British journal of clinical pharmacology. 2008, Vol 65, Num 2, pp 224-229, issn 0306-5251, 6 p.Article

A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteersCAMIDGE, D. Ross; SMETHURST, Dominic; GROWCOTT, Jim et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 3, pp 391-398, issn 0344-5704, 8 p.Article

A Phase 2 Trial of Dacomitinib (PF-00299804), an Oral, Irreversible Pan-HER (Human Epidermal Growth Factor Receptor) Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer After Failure of Prior Chemotherapy and ErlotinibRECKAMP, Karen L; GIACCONE, Giuseppe; RUIZ-GARCIA, Ana et al.Cancer. 2014, Vol 120, Num 8, pp 1145-1154, issn 0008-543X, 10 p.Article

Correlations Between the Percentage of Tumor Cells Showing an Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement, ALK Signal Copy Number, and Response to Crizotinib Therapy in ALK Fluorescence In Situ Hybridization―Positive Nonsmall Cell Lung CancerCAMIDGE, D. Ross; THEODORO, Mariana; MAXSON, Delee A et al.Cancer. 2012, Vol 118, Num 18, pp 4486-4494, issn 0008-543X, 9 p.Article

Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung CancerKWAK, Eunice L; BANG, Yung-Jue; VARELLA-GARCIA, Marileila et al.The New England journal of medicine. 2010, Vol 363, Num 18, pp 1693-1703, issn 0028-4793, 11 p.Article

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced CancerBANERJI, Udai; CAMIDGE, D. Ross; BROWN, Kathryn H et al.Clinical cancer research (Print). 2010, Vol 16, Num 5, pp 1613-1623, issn 1078-0432, 11 p.Article

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsKRIS, Mark G; JOHNSON, Bruce E; YU SHYR et al.JAMA, the journal of the American Medical Association. 2014, Vol 311, Num 19, pp 1998-2006, issn 0098-7484, 9 p.Article

Native and Rearranged ALK Copy Number and Rearranged Cell Count in Non-Small Cell Lung Cancer: Implications for ALK Inhibitor TherapyCAMIDGE, D. Ross; SKOKAN, Margaret; DOEBELE, Robert C et al.Cancer. 2013, Vol 119, Num 22, pp 3968-3975, issn 0008-543X, 8 p.Article

Symptomatic Reduction in Free Testosterone Levels Secondary to Crizotinib Use in Male Cancer PatientsWEICKHARDT, Andrew J; DOEBELE, Robert C; NIEVA, Jorge et al.Cancer. 2013, Vol 119, Num 13, pp 2383-2390, issn 0008-543X, 8 p.Article

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid TumorsGANDHI, Leena; CAMIDGE, D. Ross; DIVE, Caroline et al.Journal of clinical oncology. 2011, Vol 29, Num 7, pp 909-916, issn 0732-183X, 8 p.Article